Axonis Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule therapies that target KCC2, a key regulator of inhibitory signaling in the brain. Its lead program aims to restore synaptic balance in neurological disorders such as epilepsy and pain, addressing significant unmet needs in central nervous system disease.